What is CONTINUUMRX?
CONTINUUMRX operates as a specialized provider of home and site-based infusion therapies, serving as a vital partner to healthcare systems seeking to optimize post-acute care coordination. With over two decades of industry experience, the firm offers a comprehensive suite of services, including antibiotic therapy, enteral and parenteral nutrition, IVIG therapy, heart failure management, and biologic therapies. Accredited by the Accreditation Commission for Health Care (ACHC), the company is recognized for its rigorous quality standards and its ability to manage complex patient needs outside of traditional hospital settings. By integrating seamlessly with existing provider workflows, CONTINUUMRX enhances patient outcomes while simultaneously driving cost-efficiencies for its healthcare partners.
How much funding has CONTINUUMRX raised?
CONTINUUMRX has raised a total of $21.5M across 3 funding rounds:
Unspecified
$7M
Private Equity
$13.5M
Debt
$1M
Unspecified (2012): $7M with participation from Stonehenge Capital, Health Enterprise Partners, Mitsui & Co, and Redmont Venture Partners
Private Equity (2015): $13.5M led by NewSpring Capital
Debt (2020): $1M supported by PPP
Key Investors in CONTINUUMRX
Stonehenge Capital
Established in 1999, Stonehenge Capital is a tax-credit service, venture capital, and investment firm based in Tampa, FL.
Health Enterprise Partners
HEP Fund partners with organizations transforming the healthcare industry to enhance healthcare delivery through strategic payer and provider networks.
Mitsui & Co
Mitsui & Co. is a global trading and investment company that leverages its cross-industry expertise to deliver healthcare solutions and enhance quality of life.
What's next for CONTINUUMRX?
With the recent infusion of capital, CONTINUUMRX is poised to accelerate its strategic growth initiatives, focusing on the expansion of its infusion therapy infrastructure and the deepening of its partnerships with major healthcare systems. The company is expected to prioritize the integration of advanced clinical management tools to further streamline patient care pathways and improve therapeutic adherence. As the demand for home-based medical services continues to rise, CONTINUUMRX is strategically positioned to capitalize on this shift, leveraging its proven track record and institutional support to capture a larger share of the post-acute care market. Future efforts will likely center on scaling its geographic reach and diversifying its therapeutic offerings to address emerging patient needs in the evolving healthcare ecosystem.
See full CONTINUUMRX company page
